• The University of Oviedo leads a research that links cáncer with failure in the protection of chromosomes

    March 17, 2013

    The research, published in "Nature Genetics" and directed by Carlos López-Otín, Elías Campo (Clínic Hospital) and María Blasco (National Center of Oncological Research), detects for the first time in a human cancer the mutation of a gene that is essential to protect the telomeres.

    Mutations in POT1

    A research published by Nature Genetics, and to which the University of Oviedo has made important contributions through the University Institute of Oncology, explores a new mechanism that may contribute to the development of diverse tumors, including chronic lymphatic leukemia, a form of cancer that affects thousands of new patients each year in Spain. The researchers have detected for the first time in a human cancer the mutation of an essential gene for the protection of the telomeres, situated on the edges of the chromosomes.

    The research, directed by Carlos López-Otín, of the University Institute of Oncology of the University of Oviedo, Elías Campo, of the Clínic Hospital/University of Barcelona, and María Blasco, director of the National Center of Oncological Research (CNIO), breaks new ground for the Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia ( Apart from López-Otín, Víctor Quesada and Andrew Ramsay, members of his team, have participated in the study.

    "The chronic lymphatic leukemia is the most common type of leukemia in the Western countries", comments López-Otín, and adds: "Once the genetic and epigenetic changes in its development have been deciphered, it is necessary to understand the biochemical mechanisms altered by said changes, in order to improve the diagnosis and treatment of this disease".

    Thus, following the previous research conducted by Campo and López-Otín and published in Nature and Nature Genetics during the past two years, the researchers focused on the mutations that affect the POT1, one of the genes involved in the protection of the edges of the chromosomes, the telomeres.

    It is the first time that a gene with this function appears mutated in a human cancer. Blasco remarks: "We have been studying the biology of the telomeres for a long time, since alterations to their maintenance are associated to cancer, and to aging as well. Although some mechanisms by means of which tumorous cells alter their telomeres are known, the mutations in POT1 reveal a previously-unknown route".

    Each chromosome has on its edges, in the telomeres, a protective cover formed by proteins, and POT1 is the staple that locks it into place by joining it to the telomeric DNA. All the mutations thus found on POT1 prevent this gene from carrying out its function. The DNA of the edge of the chromosome is left, this way, without its protective cover. The research of the biochemical route that leads from these anomalies to the uncontrolled growth of B cells may shed light on key aspects of the chronic lymphatic leukemia and on cancer in general.

    One of the most frequently-mutated genes in leukemia

    Moreover, after having analyzed the genome of 341 patients of chronic lymphatic leukemia—comparing in each case the genes of healthy cells and tumorous cells—the researchers have discovered that POT1 is one of the most frequently-mutated genes in this disease.

    Previous results by the Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia had already proved that thousands of mutations are involved in this disease, and that each patient presents an unique combination of hundreds of them. One of the most significant findings of the studies of the Consortium is the great genetic and molecular diversity of the disease.

    The different mutated genes identify relatively small sub-groups of patients with different characteristics in their disease. In fact, the most-repeated mutations are only found in 15% of the patients. Nevertheless, its identification is a considerable breakthrough, since it is a step towards personalized treatment, based on the genetic profile of each tumor.

    In the research that is now being published, the researchers found that 3.5% of the patients of chronic lymphatic leukemia present mutations in POT1, but their number escalates to 9% in the group of patients of a notably aggressive form of the disease. Thus, the study identifies POT1 as one of the most important genes for this disease.

    As Campo concludes: "The patients with mutations in POT1 belong to the group with the grimmest prognosis. Thus, a therapeutic intervention that follows this route may help the treatment of a group of patients whose clinical perspective are, currently, very unfavorable".

    The Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia is financed by the Ministry of Economy and Competiveness through the Carlos III Health Institute, and is situated within the International Consortium for Cancer Genomes (ICGC) ( Three years ago, Nature highlighted the potential relevance of the results expected from the ICGC for the development of new methods of diagnosis and therapies against cancer, since the Consortium plans to coordinate in a global scale the sequencing and the analysis of more than 500 tumorous genomes of each of the 50 most-frequent types of cancer.

    Since then, Nature and Nature Genetics have published in several articles the advancements of the Spanish participants in the ICGC, based on the analysis of the genomic and epigenomic alterations of more than 100 patients of chronic lymphatic leukemia. The new research published by Nature Genetics goes deeper in one of the most outstanding discoveries derived from those early studies, and contributes to emphasize the relevance of the dynamics of the telomeres, decisive structures for a better understanding of process as complex as cancer and aging.

    The Spanish contribution to the International Consortium combines the work of more than a dozen of institutions, including the Clínic Hospital of Barcelona, the University of Barcelona, the University Institute of Oncology of the University of Oviedo, the Genomic Regulation Center of Barcelona, the Catalan Institute of Oncology, the Center for Cancer Research of Salamanca, the National Bank of DNA, the National Center for Oncological Research, the University of Deusto, the University of Santiago de Compostela, the Barcelona Supercomputing Center, the National Center for Genomic Analysis and the August Pi i Sunier Institute of Biomedical Research.

    Key aspects of the study
    • The work of the Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia has detected the frequent appearance of mutations of the POT1 gene in patients of the most-aggressive form of the disease.
    • POT1 is a necessary factor for the proper functioning of the protective complex of the telomeres, which maintains the integrity of the chromosomes.
    • The research carried out during several decades by the Clínic Hospital of Barcelona on chronic lymphatic leukemia has allowed the Consortium to have clinical samples and data of a group of patients with mutations in POT1.
    • Joint biochemical studies by the University of Oviedo and the National Center for Oncological Research have proved that the mutations in POT1 are part of a new mechanism for the development of the cancer.

    Signatories of the article:

    Andrew J Ramsay, Víctor Quesada, Miguel Foronda, Laura Conde, Alejandra Martínez-Trillos, Neus Villamor, David Rodríguez, Agnieszka Kwarciak, Cecilia Garabaya, Mercedes Gallardo, Mónica López-Guerra, Armando López-Guillermo, Xose S Puente, María A Blasco, Elías Campo y Carlos López-Otín.